Some blind vision loss cases have been linked to the use of weight-loss jabs, including Ozempic, so caution is recommended by ...

New research shows GLP-1 drugs may be linked to a twofold increase in the risk of wet AMD among people with diabetes.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Older adults with diabetes who are using semaglutide are twice as likely to develop neovascular age-related macular ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The European Medicines Agency (EMA) has warned that popular weight-loss and diabetes drugs containing semaglutide — including ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...